Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Former Justice Department paralegal Sean Dunn, who went viral this summer for chucking a Subway sandwich at a Customs and ...

Two groups are fighting for an edge in one of the most lucrative drug classes in the pharmaceutical industry’s history.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Two years later, those treatments have thrust Metsera to the centre of a fierce takeover battle, with Ozempic maker Novo Nordisk and Pfizer willing to pay up to $10bn for the company. Both once again ...

To get a sense of who is truly in control of Pfizer Inc. (NYSE:PFE), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same ...

Sunday 9 November 2025 marks the fifth anniversary of a defining moment in stock market history. Pfizer/BioNTech’s ...

Pfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's ...

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s ...